DOI: https://doi.org/10.22141/2224-0721.3.59.2014.76668

Diabetic Retinopathy: a New Approach to Drug Treatment

V.I. Pankiv

Abstract


Diabetic retinopathy is a basic microvascular complication of diabetes and the leading cause of blindness in the adult population. A review of the literature on this pathology, a relatively new approach to medical treatment of this complication of diabetes.


References


Fong D.S., Aiello L., Gardner T.W. et al. American Diabetes Association. Retinopathy in diabetes // Diabetes Care. — 2004. — Vol. 27, suppl. 1. — S. 84-S87.

Сheung N., Wong T.Y. Diabetic retinopathy and systemic vascular complications // Prog. Retin. Eye Res. — 2008. — Vol. 27(2). — P. 161-176.

Liew G., Wong T.Y., Mitchell P. et al. Retinopathy predicts coronary heart disease mortality // Heart. — 2009. — Vol. 95(5). — P. 391-394.

Vijan S., Hofer T.P., Hayward R.A. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus // JAMA. — 2000. — Vol. 283(7). — P. 889-896.

Kempen J.H., O’Colmain B.J., Leske M.C. et al. Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States // Arch. Ophthalmol. — 2004. — Vol. 122(4). — P. 552-563.

Hovind P., Tarnow L., Rossing K. et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes // Diabetes Care. — 2003. — Vol. 26(4). — P. 1258-1264.

Nordwall M., Bojestig M., Arnqvist H.J. et al. Diabetes Complications Study. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of type 1 diabetes // Diabetologia. — 2004. — Vol. 47(7). — P. 1266-1272.

Bloomgarden Z.T., Drexler A. Fibrate use in diabetes. New concepts // J. Diabetes. — 2011. — Vol. 3(1). — P. 1-2.

Ansquer J.C., Foucher C., Rattier S. et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) // Am. J. Kidney Dis. — 2005. — Vol. 45(3). — P. 485-493.

Keech A., Simes R.J., Barter P. et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial // Lancet. — 2005. — Vol. 366. — P. 1849-1861.

Keech A., Mitchell P., Summanen P.A. et al. FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial // Lancet. — 2007. — Vol. 370. — P. 1687-1697.

Forsblom C., Hiukka A., Leinonen E.S. et al. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy // Diabetes Care. — 2010. — 33. — P. 215-220.

Keating G.M. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus // Am. J. Cardiovasc. Drugs. — 2011. — Vol. 11(4). — P. 227-247.

ACCORD Study Group; ACCORD Eye Study Group, Chew E.Y., Ambrosius W.T., Davis M.D. et al. Effects of medical therapies on retinopathy progression in type 2 diabetes // N. Engl. J. Med. — 2010. — Vol. 363. — P. 233-244.

Уніфікований клінічний протокол первинної та вторинної (спеціалізованої) медичної допомоги цукрового діабету 2 типу. Наказ Міністерства охорони здоров’я від 21.12.2012 № 1118. — 118 с.

Протокол надання медичної допомоги хворим з діабетичною ретинопатією. Наказ МОЗ України від 15.03.2007 № 117.

Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study // Lancet. — 2001. — 357. — 905-10.






Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта